<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="78782">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079857</url>
  </required_header>
  <id_info>
    <org_study_id>12-02325</org_study_id>
    <secondary_id>R01NR013695</secondary_id>
    <nct_id>NCT02079857</nct_id>
  </id_info>
  <brief_title>Symptom Management for Irritable Bowel Syndrome</brief_title>
  <official_title>Symptom Management for Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <brief_summary>
    <textblock>
      The objective of this study is to test the efficacy of a symptom management treatment
      strategy, Acupuncture/Moxibustion (Acu/Moxa), to improve the symptoms associated with
      Irritable Bowel Syndrome (IBS) in adults.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom severity-abdominal pain</measure>
    <time_frame>week 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom severity-abdominal pain</measure>
    <time_frame>week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom severity-abdominal pain</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom severity-abdominal pain</measure>
    <time_frame>week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom severity-abdominal pain</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">183</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individualized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized protocol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham acupuncture/Placebo moxa</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard protocol</intervention_name>
    <description>Subjects will receive a standard treatment</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Individualized protocol</intervention_name>
    <description>Subjects will receive an individualized treatment</description>
    <arm_group_label>Individualized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham acupuncture/Placebo moxa</intervention_name>
    <description>Subjects will receive sham acupuncture/placebo moxa</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 to 70 years of age.

          -  Diagnosis of IBS based on ROME III criteria.

          -  Complete symptom diaries and return completed diaries at all sessions.

        Exclusion Criteria:

          -  History of co-existing gastrointestinal, and/or gynecological, and/or urologic
             pathology.

          -  Alarm symptoms according to ROME III.

          -  Individuals currently receiving other types of complementary therapies.

          -  Individuals with an acute medical condition requiring acute medical attention.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Joyce K Anastasi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Division of Special Studies in Symptom Management</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Scully</last_name>
      <phone>212-992-7051</phone>
    </contact>
    <investigator>
      <last_name>Dr. Joyce K Anastasi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 7, 2016</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
